These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34328096)

  • 1. Development of a novel anti-B7-H4 antibody enhances anti-tumor immune response of human T cells.
    Miao G; Sun X
    Biomed Pharmacother; 2021 Sep; 141():111913. PubMed ID: 34328096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity.
    Xu Y; Xiao Y; Luo C; Liu Q; Wei A; Yang Y; Zhao L; Wang Y
    Int Immunopharmacol; 2020 Jul; 84():106584. PubMed ID: 32422527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
    Dangaj D; Lanitis E; Zhao A; Joshi S; Cheng Y; Sandaltzopoulos R; Ra HJ; Danet-Desnoyers G; Powell DJ; Scholler N
    Cancer Res; 2013 Aug; 73(15):4820-9. PubMed ID: 23722540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of host B7-H4 deficiency and gemcitabine treatment on tumor regression and anti-tumor T cell immunity in a mouse model.
    Leung J; St-Onge P; Stagg J; Suh WK
    Cancer Immunol Immunother; 2017 Apr; 66(4):491-502. PubMed ID: 28074226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic Suppression of B7-H4 Glycosylation Restores Antitumor Immunity in Immune-Cold Breast Cancers.
    Song X; Zhou Z; Li H; Xue Y; Lu X; Bahar I; Kepp O; Hung MC; Kroemer G; Wan Y
    Cancer Discov; 2020 Dec; 10(12):1872-1893. PubMed ID: 32938586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The anti-B7-H4 checkpoint synergizes trastuzumab treatment to promote phagocytosis and eradicate breast cancer.
    Hu X; Liu Y; Zhang X; Kong D; Kong J; Zhao D; Guo Y; Sun L; Chu L; Liu S; Hou X; Ren F; Zhao Y; Lu C; Zhai D; Yuan X
    Neoplasia; 2020 Nov; 22(11):539-553. PubMed ID: 32966956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Co-inhibitory Molecule B7 Superfamily Member 1 Expressed by Tumor-Infiltrating Myeloid Cells Induces Dysfunction of Anti-tumor CD8
    Li J; Lee Y; Li Y; Jiang Y; Lu H; Zang W; Zhao X; Liu L; Chen Y; Tan H; Yang Z; Zhang MQ; Mak TW; Ni L; Dong C
    Immunity; 2018 Apr; 48(4):773-786.e5. PubMed ID: 29625896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.
    Iizuka A; Kondou R; Nonomura C; Ashizawa T; Ohshima K; Kusuhara M; Isaka M; Ohde Y; Yamaguchi K; Akiyama Y
    Oncol Rep; 2016 Nov; 36(5):2625-2632. PubMed ID: 27632942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B7-H4 overexpression impairs the immune response of T cells in human cervical carcinomas.
    Wang X; Wang T; Xu M; Xiao L; Luo Y; Huang W; Zhang Y; Geng W
    Hum Immunol; 2014 Dec; 75(12):1203-9. PubMed ID: 25446402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fully human anti-B7-H3 recombinant antibodies inhibited tumor growth by increasing T cell infiltration.
    Li L; Nian S; Liu Q; Zhang B; Jimu W; Li C; Huang Z; Hu Q; Huang Y; Yuan Q
    Int Immunopharmacol; 2024 May; 132():111926. PubMed ID: 38552297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H4 reduces the infiltration of CD8+T cells and induces their anti-tumor dysfunction in gliomas.
    Qi Y; Hu L; Ji C; Yang X; Yao J; Chen D; Yao Y
    Neoplasia; 2024 Aug; 54():101007. PubMed ID: 38796932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H4 expression by nonhematopoietic cells in the tumor microenvironment promotes antitumor immunity.
    Rahbar R; Lin A; Ghazarian M; Yau HL; Paramathas S; Lang PA; Schildknecht A; Elford AR; Garcia-Batres C; Martin B; Berman HK; Leong WL; McCready DR; Reedijk M; Done SJ; Miller N; Youngson B; Suh WK; Mak TW; Ohashi PS
    Cancer Immunol Res; 2015 Feb; 3(2):184-95. PubMed ID: 25527357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of avian-derived anti-B7-H4 antibodies exerts a blockade effect on the immunosuppressive response.
    Lin TY; Tsai TH; Chen CT; Yang TW; Chang FL; Lo YN; Chung TS; Cheng MH; Chen WC; Tsai KC; Lee YC
    Exp Anim; 2021 Aug; 70(3):333-343. PubMed ID: 33716253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Host B7-H4 regulates antitumor T cell responses through inhibition of myeloid-derived suppressor cells in a 4T1 tumor transplantation model.
    Leung J; Suh WK
    J Immunol; 2013 Jun; 190(12):6651-61. PubMed ID: 23686485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of Immune-Checkpoint B7-H4 and Lysine Demethylase 5B in Esophageal Squamous Cell Carcinoma Confers Protective Immunity against
    Yuan X; Liu Y; Li G; Lan Z; Ma M; Li H; Kong J; Sun J; Hou G; Hou X; Ma Y; Ren F; Zhou F; Gao S
    Cancer Immunol Res; 2019 Sep; 7(9):1440-1456. PubMed ID: 31350278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blocking of the PD-1/PD-L1 interaction by a novel cyclic peptide inhibitor for cancer immunotherapy.
    Zhai W; Zhou X; Zhai M; Li W; Ran Y; Sun Y; Du J; Zhao W; Xing L; Qi Y; Gao Y
    Sci China Life Sci; 2021 Apr; 64(4):548-562. PubMed ID: 32737851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Pathways: Evaluating the Potential for B7-H4 as an Immunoregulatory Target.
    MacGregor HL; Ohashi PS
    Clin Cancer Res; 2017 Jun; 23(12):2934-2941. PubMed ID: 28325750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody.
    Ha D; Tanaka A; Kibayashi T; Tanemura A; Sugiyama D; Wing JB; Lim EL; Teng KWW; Adeegbe D; Newell EW; Katayama I; Nishikawa H; Sakaguchi S
    Proc Natl Acad Sci U S A; 2019 Jan; 116(2):609-618. PubMed ID: 30587582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.